Muridda provides immunology services to support the preclinical development of immunotoxicity assessment and immunogenicity analysis. Through the analysis of preclinical and clinical samples, method development and validation, as well as immunogenicity and immunotoxicity studies, we support our clients’ drug development needs.
The immune system is a highly specific and challenging drug target. Our technology platforms include immunochemistry, immunohistochemistry, flow cytometry, HELISA, GPCR and high‑throughput sequencing. All study designs comply with international guidelines to meet GLP regulatory submission requirements.
Test articles we can evaluate include antibodies, recombinant proteins, peptides, antibody‑drug conjugates, antisense oligonucleotides, siRNA and vaccines. We also provide tailored immunology consulting services according to clients’ specific requirements.
Service Items
- Immunohistology and pathological morphology
- Immunohistochemistry
- Immunochemistry (ELISAs, IgG, C3)
- Protein toxicokinetics
- Immunogenicity, anti‑drug antibodies, neutralizing antibodies, cytokine quantification
- Flow cytometry
- Biopsy
- TDAR (T‑cell‑dependent antibody response)
- Biopharmaceutical formulation analysis
- Biopharmaceutical PK/TK: based on LBA, HELISA, qPCR, etc.
- Immunophenotyping analysis
- T‑cell‑dependent antibody response (TDAR)
- Tissue cross‑reactivity (TCR)
- Biomarker analysis